Related Experiment Video
Updated: Jun 30, 2025
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Unveiling therapeutic prospects: targeting MDM-2 in non-muscle invasive bladder cancer
Hongjian Wu1, Hui Jin2, Yongjian Cai1
1Department of Urology, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Taizhou, Zhejiang, China.
Abstract:
Non-muscle invasive bladder cancer (NMIBC) is considered one of the most costly malignancies, requiring significant surgical and therapeutic measures. However, progression and non-responsiveness to immunotherapy are common outcomes of treatment. In this study, we conducted comparative transcriptomic analysis of non-responders from two distinct populations (Asian and American) and identified six common genes associated with disease prognosis. Among these genes, MDM-2 is a major oncogenic protein linked to seven different types of cancers, as it is involved in the degradation of the tumor suppressor protein p53. To address this, we explored novel therapeutic drugs to block the binding of p53 and MDM-2 using a targeted molecular docking approach. High-throughput screening of 2500 drugs from the FDA-approved drug database led to the identification of three drug compounds: Mol-126, Mol-679, and Mol-768. Subsequently, we evaluated the structural stability and binding of these drugs for the targeted inhibition of the MDM-2 active site (hydrophobic cleft) using molecular dynamics simulations. Analysis of five trajectories, including RMSD, RMSF, hydrogen bond, radius of gyration, coulomb short-range electrostatic spectra, and free binding energy, confirmed that Mol-126 exhibited the highest structural stability compared to the reference drug (Alrizomadlin). Notably, Mol-126 is a derivative of 3-phenoxypropionic acid, which shows promise for the development of alternative therapeutic treatments for non-responsive bladder cancer patients.
Insights
This study identifies MDM-2 as a key gene in non-muscle invasive bladder cancer (NMIBC) non-responders. A novel drug, Mol-126, shows promise in blocking MDM-2 activity for new bladder cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Non-muscle invasive bladder cancer (NMIBC) presents significant treatment challenges, with frequent progression and immunotherapy non-responsiveness.
- MDM-2 oncogenic protein degrades the tumor suppressor p53, contributing to various cancers, including bladder cancer.
- Identifying novel therapeutic targets and drugs is crucial for improving outcomes in NMIBC patients.
Purpose of the Study:
- To identify common genes associated with prognosis in NMIBC non-responders across different populations.
- To explore novel therapeutic agents targeting the MDM-2/p53 interaction for bladder cancer treatment.
- To evaluate the efficacy and stability of identified drug candidates using computational methods.
Main Methods:
- Comparative transcriptomic analysis of NMIBC non-responders from Asian and American populations.
- High-throughput screening of FDA-approved drugs to identify inhibitors of MDM-2/p53 binding.
- Molecular docking and molecular dynamics simulations to assess drug-target interactions and stability.
Main Results:
- Six common genes were identified, with MDM-2 highlighted for its role in p53 degradation.
- Three potential drug compounds (Mol-126, Mol-679, Mol-768) were identified from screening 2500 FDA-approved drugs.
- Mol-126 demonstrated superior structural stability and binding affinity to the MDM-2 active site compared to a reference drug, Alrizomadlin.
Conclusions:
- MDM-2 is a significant oncogenic factor in bladder cancer non-responders.
- Mol-126, a 3-phenoxypropionic acid derivative, shows potential as a novel therapeutic agent for NMIBC.
- This research offers a promising avenue for developing alternative treatments for immunotherapy-resistant bladder cancer.
